BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005;35:316-323. [PMID: 15961436 DOI: 10.1093/jjco/hyi095] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol 2022;:JCO2200686. [PMID: 35969830 DOI: 10.1200/JCO.22.00686] [Reference Citation Analysis]
2 Kawamoto T, Shikama N, Mine S, Sasai K. Comparison of Recurrence Patterns and Salvage Treatments After Definitive Radiotherapy for cT1a and cT1bN0M0 Esophageal Cancer. Front Oncol 2022;12:857881. [DOI: 10.3389/fonc.2022.857881] [Reference Citation Analysis]
3 Suwa T, Ishida Y, Negoro Y, Kusumi F, Kadokawa Y, Aizawa R, Nakajima T, Okamoto Y, Okuno Y, Yamada K, Ogura M, Murakami M, Mizowaki T. Long-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma. Clin Transl Radiat Oncol 2021;30:88-94. [PMID: 34430719 DOI: 10.1016/j.ctro.2021.08.002] [Reference Citation Analysis]
4 Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, Ueno M, Nakagawa S, Takagi M, Tsunoda S, Abe T, Nakamura T, Okada M, Toh Y, Shibuya Y, Yamamoto S, Katayama H, Nakamura K, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 2021:S0016-5085(21)03352-7. [PMID: 34389340 DOI: 10.1053/j.gastro.2021.08.007] [Reference Citation Analysis]
5 Mori K, Sugawara K, Aikou S, Yamashita H, Yamashita K, Ogura M, Chin K, Watanabe M, Matsubara H, Toh Y, Kakeji Y, Seto Y. Esophageal cancer patients' survival after complete response to definitive chemoradiotherapy: a retrospective analysis. Esophagus 2021;18:629-37. [PMID: 33625649 DOI: 10.1007/s10388-021-00817-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yamamoto Y, Kadota T, Yoda Y, Hori K, Hatogai K, Kojima T, Fujii S, Akimoto T, Yano T. Review of early endoscopic findings in patients with local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus 2020;17:433-9. [PMID: 32232702 DOI: 10.1007/s10388-020-00734-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sato D, Motegi A, Kadota T, Kojima T, Bando H, Shinmura K, Hori K, Yoda Y, Oono Y, Zenda S, Ikematsu H, Akimoto T, Yano T. Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence. Esophagus 2020;17:305-11. [PMID: 31965362 DOI: 10.1007/s10388-020-00715-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Fassan M, Cavallin F, Guzzardo V, Kotsafti A, Scarpa M, Cagol M, Chiarion-Sileni V, Maria Saadeh L, Alfieri R, Castagliuolo I, Rugge M, Castoro C, Scarpa M. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Cancer Med 2019;8:6036-48. [PMID: 31429521 DOI: 10.1002/cam4.2359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
9 Akiyama Y, Iwaya T, Endo F, Nikai H, Baba S, Chiba T, Kimura T, Takahara T, Otsuka K, Nitta H, Mizuno M, Kimura Y, Koeda K, Sasaki A. Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma. Asian J Endosc Surg 2020;13:152-9. [PMID: 31313511 DOI: 10.1111/ases.12731] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Kadota T, Abe S, Yoda Y, Yoshinaga S, Oda I, Kojima T, Kato K, Daiko H, Yano T. Clinical outcomes according to the modified endoscopic criteria for neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma. Dig Endosc 2020;32:337-45. [PMID: 31295769 DOI: 10.1111/den.13483] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Qian D, Wang Y, Zhao G, Cao F, Er P, Chen X, Cheng J, Zhang W, Li X, Zhang B, Guan Y, Zhou D, Wang J, Jiang H, Yu Z, Yuan Z, Wang P, Pang Q. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:319-28. [PMID: 31228553 DOI: 10.1016/j.ijrobp.2019.06.079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
12 Wang J, Yu JP, Ni XC, Sun ZQ, Sun W, Nie B, Sun SP, Wang JL. Pathological response and serum VEGF changes during chemoradiotherapy for esophageal carcinoma. Medicine (Baltimore) 2019;98:e15627. [PMID: 31096474 DOI: 10.1097/MD.0000000000015627] [Reference Citation Analysis]
13 Sun Y, Zhang XL, Mao QF, Liu YH, Kong L, Li MH. Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients. Curr Oncol 2018;25:e423-9. [PMID: 30464693 DOI: 10.3747/co.25.3895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ishibashi N, Hata M, Maebayashi T, Aizawa T, Sakaguchi M, Okada M. Does protruding type 1 esophageal cancer really have a good response to radiation therapy?-a retrospective observational study. J Thorac Dis 2018;10:3512-8. [PMID: 30069348 DOI: 10.21037/jtd.2018.05.103] [Reference Citation Analysis]
15 Wang Y, Cheng J, Xie D, Ding X, Hou H, Chen X, Er P, Zhang F, Zhao L, Yuan Z, Pang Q, Wang P, Qian D. NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc. Cancer Commun (Lond) 2018;38:33. [PMID: 29871674 DOI: 10.1186/s40880-018-0307-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kobuchi S, Ito Y, Sakaeda T. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats. Eur J Drug Metab Pharmacokinet 2017;42:707-18. [PMID: 27889876 DOI: 10.1007/s13318-016-0389-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
17 Kozumi M, Ota H, Yamamoto T, Umezawa R, Matsushita H, Ishikawa Y, Takahashi N, Matsuura T, Takase K, Jingu K. Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy. Eur Radiol 2018;28:4296-305. [PMID: 29725833 DOI: 10.1007/s00330-018-5439-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Liw P, Wen Y, Tsai C, Chang H, Tseng C, Hung T, Chao Y. Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy. The Journal of Thoracic and Cardiovascular Surgery 2018;155:2233-2242.e2. [DOI: 10.1016/j.jtcvs.2017.12.082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Saito T. Clinical results of multimodality therapy for esophageal cancer with distant metastasis. J Thorac Dis 2018;10:1500-10. [PMID: 29707300 DOI: 10.21037/jtd.2018.03.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Wen Y, Zhao Z, Miao J, Yang Q, Gui Y, Sun M, Tian H, Jia Q, Liao D, Yang C, Du X. S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial. Medicine (Baltimore) 2017;96:e8998. [PMID: 29245275 DOI: 10.1097/MD.0000000000008998] [Reference Citation Analysis]
21 Hombu T, Yano T, Hatogai K, Kojima T, Kadota T, Onozawa M, Yoda Y, Hori K, Oono Y, Ikematsu H, Fujii S. Salvage endoscopic resection (ER) after chemoradiotherapy for esophageal squamous cell carcinoma: What are the risk factors for recurrence after salvage ER? Dig Endosc 2018;30:338-46. [PMID: 29106753 DOI: 10.1111/den.12984] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
22 Yano T, Kasai H, Horimatsu T, Yoshimura K, Teramukai S, Morita S, Tada H, Yamamoto Y, Kataoka H, Kakushima N, Ishihara R, Isomoto H, Muto M. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 2017;8:22135-44. [PMID: 28212527 DOI: 10.18632/oncotarget.14029] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
23 Chao Y, Chuang W, Yeh C, Chang H, Tseng C. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy. European Journal of Cardio-Thoracic Surgery 2018;53:201-8. [DOI: 10.1093/ejcts/ezx261] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
24 Zenda S, Kojima T, Kato K, Izumi S, Ozawa T, Kiyota N, Katada C, Tsushima T, Ito Y, Akimoto T, Hasegawa Y, Kanamaru M, Daiko H. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus. International Journal of Radiation Oncology*Biology*Physics 2016;96:976-84. [DOI: 10.1016/j.ijrobp.2016.08.045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
25 Ji Y, Qiu G, Sheng L, Sun X, Zheng Y, Chen M, Du X. A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis 2016;8:451-8. [PMID: 27076940 DOI: 10.21037/jtd.2016.02.70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
26 Hatogai K, Yano T, Kojima T, Onozawa M, Daiko H, Nomura S, Yoda Y, Doi T, Kaneko K, Ohtsu A. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2016;83:1130-1139.e3. [PMID: 26608125 DOI: 10.1016/j.gie.2015.11.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
27 Cheng J, Liu W, Zeng X, Zhang B, Guo Y, Qiu M, Jiang C, Wang H, Wu Z, Meng M, Zhuang H, Zhao L, Hao J, Cai Q, Xie D, Pang Q, Wang P, Yuan Z, Qian D. XRCC3 is a promising target to improve the radiotherapy effect of esophageal squamous cell carcinoma. Cancer Sci. 2015;106:1678-1686. [PMID: 26383967 DOI: 10.1111/cas.12820] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
28 Kobuchi S, Ito Y, Nakano Y, Sakaeda T. Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. Xenobiotica 2015;46:597-604. [DOI: 10.3109/00498254.2015.1100767] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tahara M, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K, Kato K, Yamazaki K, Muro K, Takaishi H. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). Cancer Sci. 2015;106:1414-1420. [PMID: 26250827 DOI: 10.1111/cas.12764] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
30 Chao YK, Yeh CJ, Lee MH, Wen YW, Chang HK, Tseng CK, Liu YH. Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) 2015;94:e588. [PMID: 25715265 DOI: 10.1097/MD.0000000000000588] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Qian D, Zhang B, Zeng XL, Le Blanc JM, Guo YH, Xue C, Jiang C, Wang HH, Zhao TS, Meng MB, Zhao LJ, Hao JH, Wang P, Xie D, Lu B, Yuan ZY. Inhibition of human positive cofactor 4 radiosensitizes human esophageal squmaous cell carcinoma cells by suppressing XLF-mediated nonhomologous end joining. Cell Death Dis. 2014;5:e1461. [PMID: 25321468 DOI: 10.1038/cddis.2014.416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
32 Takahashi T, Yamahsita S, Matsuda Y, Kishino T, Nakajima T, Kushima R, Kato K, Igaki H, Tachimori Y, Osugi H, Nagino M, Ushijima T. ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. J Cancer Res Clin Oncol 2015;141:453-63. [PMID: 25273507 DOI: 10.1007/s00432-014-1841-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
33 Kawasaki Y, Okumura H, Uchikado Y, Kita Y, Sasaki K, Owaki T, Ishigami S, Natsugoe S. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol 2014;21:2347-52. [PMID: 24599410 DOI: 10.1245/s10434-014-3600-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
34 Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14. [PMID: 24556041 DOI: 10.1016/S1470-2045(14)70028-2] [Cited by in Crossref: 207] [Cited by in F6Publishing: 99] [Article Influence: 25.9] [Reference Citation Analysis]
35 Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2014;11:321-6. [PMID: 24578608 DOI: 10.7150/ijms.7654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
36 Tsurumaru D, Hiraka K, Komori M, Shioyama Y, Morita M, Honda H. Role of barium esophagography in patients with locally advanced esophageal cancer: evaluation of response to neoadjuvant chemoradiotherapy. Radiol Res Pract 2013;2013:502690. [PMID: 24369500 DOI: 10.1155/2013/502690] [Reference Citation Analysis]
37 Adenis A, Tresch E, Dewas S, Romano O, Messager M, Amela E, Clisant S, Kramar A, Mariette C, Mirabel X. Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 2013;13:413. [PMID: 24010566 DOI: 10.1186/1471-2407-13-413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
38 Ogura M, Takeuchi H, Kawakubo H, Nishi T, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Miyasho T, Yamada S, Kitagawa Y. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery 2013;154:512-20. [DOI: 10.1016/j.surg.2013.06.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
39 Castoro C, Scarpa M, Cagol M, Alfieri R, Ruol A, Cavallin F, Michieletto S, Zanchettin G, Chiarion-sileni V, Corti L, Ancona E. Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary? J Gastrointest Surg 2013;17:1375-81. [DOI: 10.1007/s11605-013-2269-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
40 Chao Y, Tseng C, Wen Y, Liu Y, Wan Y, Chiu C, Chang W, Chang H. Using Pretreatment Tumor Depth and Length to Select Esophageal Squamous Cell Carcinoma Patients for Nonoperative Treatment After Neoadjuvant Chemoradiotherapy. Ann Surg Oncol 2013;20:3000-8. [DOI: 10.1245/s10434-013-2962-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
41 Qian D, Zhang B, He LR, Cai MY, Mai SJ, Liao YJ, Liu YH, Lin MC, Bian XW, Zeng YX, Huang JJ, Kung HF, Xie D. The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas. J Pathol 2013;229:765-74. [PMID: 23341363 DOI: 10.1002/path.4163] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
42 Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus 2013;26:708-15. [PMID: 23350713 DOI: 10.1111/dote.12019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Iwase H, Shimada M, Tsuzuki T, Hirashima N, Okeya M, Hibino Y, Ryuge N, Yokoi M, Kida Y, Kuno T, Tanaka Y, Kato B, Esaki M, Urata N, Kato E. Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial. Oncology 2013;84:342-9. [DOI: 10.1159/000348383] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
44 Zhang JX, Tong ZT, Yang L, Wang F, Chai HP, Zhang F, Xie MR, Zhang AL, Wu LM, Hong H, Yin L, Wang H, Wang HY, Zhao Y. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer 2013;132:2567-77. [PMID: 23132660 DOI: 10.1002/ijc.27930] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
45 Minegaki T, Takara K, Hamaguchi R, Tsujimoto M, Nishiguchi K. Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett 2013;5:427-34. [PMID: 23420099 DOI: 10.3892/ol.2012.1014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
46 Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2012;9:833-7. [PMID: 23155356 DOI: 10.7150/ijms.4914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
47 Hojo H, Zenda S, Akimoto T, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, Hayashi R, Sasai K. Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. J Radiat Res 2012;53:704-9. [PMID: 22843360 DOI: 10.1093/jrr/rrs021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
48 Chao Y, Liu H, Hsieh M, Wu Y, Liu Y, Yeh C, Chang H, Tseng C. Lymph Node Dissection after Chemoradiation in Esophageal Cancer: A Subgroup Analysis of Patients With and Without Pathological Response. Ann Surg Oncol 2012;19:3500-5. [DOI: 10.1245/s10434-012-2402-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
49 Kuwahara A, Yamamori M, Kadoyama K, Nishiguchi K, Nakamura T, Miki I, Tamura T, Okuno T, Omatsu H, Sakaeda T. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2011;30:94. [PMID: 21970688 DOI: 10.1186/1756-9966-30-94] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
50 Ishihara R, Yamamoto S, Iishi H, Nagai K, Matui F, Kawada N, Ohta T, Kanzaki H, Hanafusa M, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Sugimoto N, Kawaguchi Y, Nishiyama K, Motoori M, Yano M, Hosoki T. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol 2012;17:225-32. [PMID: 21735356 DOI: 10.1007/s10147-011-0278-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
51 Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 2011;41:964-72. [PMID: 21742654 DOI: 10.1093/jjco/hyr088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
52 Barthel JS, Kucera S, Harris C, Canchi D, Hoffe S, Meredith K. Cryoablation of persistent Barrett’s epithelium after definitive chemoradiation therapy for esophageal adenocarcinoma. Gastrointest Endosc. 2011;74:51-57. [PMID: 21549371 DOI: 10.1016/j.gie.2011.03.1121] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
53 Taniguchi H, Yamazaki K, Boku N, Funakoshi T, Hamauchi S, Tsushima T, Todaka A, Sakamoto T, Tomita H, Machida N, Taku K, Fukutomi A, Onozawa Y, Tsubosa Y, Sato H, Nishimura T, Yasui H. Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta. Int J Clin Oncol 2011;16:359-65. [PMID: 21347631 DOI: 10.1007/s10147-011-0192-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
54 Tsuda T, Inaba H, Miyazaki A, Izawa N, Hirakawa M, Watanabe Y, Kitajima S, Hoshikawa Y, Gomi H, Kimura M, Itoh F. Prospective study of definitive chemoradiotherapy with S-1 and nedaplatin in patients with stage II/III (non-T4) esophageal cancer. Esophagus 2011;8:45-51. [DOI: 10.1007/s10388-011-0261-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
55 Zhu W, You Z, Li T, Yu C, Tao G, Hu M, Chen X. Correlation of hedgehog signal activation with chemoradiotherapy sensitivity and survival in esophageal squamous cell carcinomas. Jpn J Clin Oncol. 2011;41:386-393. [PMID: 21127038 DOI: 10.1093/jjco/hyq217] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
56 Conroy T, Yataghène Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103:1349-1355. [PMID: 20940718 DOI: 10.1038/sj.bjc.6605943] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
57 Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010;29:100. [PMID: 20646319 DOI: 10.1186/1756-9966-29-100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
58 He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF, Xie D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 2010;127:138-47. [PMID: 19904743 DOI: 10.1002/ijc.25031] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
59 Yoshida T, Seike J, Miyoshi T, Yamai H, Takechi H, Yuasa Y, Furukita Y, Yamamoto Y, Umemoto A, Tangoku A. Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus. Esophagus 2010;7:95-100. [DOI: 10.1007/s10388-010-0234-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
60 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 2010;7:48-54. [PMID: 20151048 DOI: 10.7150/ijms.7.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
61 Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:123-129. [PMID: 19386426 DOI: 10.1016/j.ijrobp.2009.01.038] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
62 He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY, Zeng YX, Xie D. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009;9:461. [PMID: 20028503 DOI: 10.1186/1471-2407-9-461] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
63 Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer 2009;9:408. [PMID: 19930599 DOI: 10.1186/1471-2407-9-408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
64 Zenda S, Hironaka S, Taku K, Sato H, Hashimoto T, Hasuike N, Boku N, Tsubosa Y, Ono H, Nishimura T. OPTIMAL TIMING OF ENDOSCOPIC EVALUATION OF THE PRIMARY SITE OF ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY OR RADIOTHERAPY: A RETROSPECTIVE ANALYSIS. Digestive Endoscopy 2009;21:245-51. [DOI: 10.1111/j.1443-1661.2009.00900.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
65 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2009;6:305-11. [PMID: 19834547 DOI: 10.7150/ijms.6.305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
66 Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, Shiratori T, Miyazawa Y, Ito H, Uno T. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg 2009;33:1002-9. [PMID: 19247705 DOI: 10.1007/s00268-008-9899-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
67 Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009;61:388-401. [PMID: 19135108 DOI: 10.1016/j.addr.2008.10.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
68 Sun L, Su XH, Guan YS, Pan WM, Luo ZM, Wei JH, Zhao L, Wu H. Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy. World J Gastroenterol 2009; 15(15): 1836-1842 [PMID: 19370780 DOI: 10.3748/wjg.15.1836] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
69 Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit 2008;30:497-503. [PMID: 18641541 DOI: 10.1097/FTD.0b013e318180e3d2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
70 Zenda S, Hironaka S, Boku N, Yamazaki K, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Nishimura T. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 2008;21:195-200. [PMID: 18430098 DOI: 10.1111/j.1442-2050.2007.00750.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
71 Hayashi K, Motoyama S, Sugiyama T, Izumi J, Anbai A, Nanjo H, Watanabe H, Maruyama K, Minamiya Y, Koyota S. REG Ialpha is a reliable marker of chemoradiosensitivity in squamous cell esophageal cancer patients. Ann Surg Oncol. 2008;15:1224-1231. [PMID: 18259819 DOI: 10.1245/s10434-008-9810-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
72 Nonoshita T, Sasaki T, Hirata H, Toh Y, Shioyama Y, Nakamura K, Honda H. High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiat Med 2007;25:373-7. [DOI: 10.1007/s11604-007-0152-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
73 Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 2007;30:252-7. [PMID: 17551301 DOI: 10.1097/01.coc.0000256059.88247.25] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
74 Uno T, Isobe K, Kawakami H, Ueno N, Shimada H, Matsubara H, Okazumi S, Nabeya Y, Shiratori T, Kawata T, Ochiai T, Ito H. Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Diseases of the Esophagus 2007;20:12-8. [DOI: 10.1111/j.1442-2050.2007.00632.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
75 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
76 Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031-1039. [PMID: 16616487 DOI: 10.1016/j.ejca.2006.01.026] [Cited by in Crossref: 321] [Cited by in F6Publishing: 293] [Article Influence: 20.1] [Reference Citation Analysis]